Menarini & Ryvu's Phase II Results Offer Hope in B-NHL
New Glimmers of Hope in B-cell NHL Battle Battling aggressive B-cell non-Hodgkin lymphoma (B-NHL) isn't for the faint of heart, especially when standard treatments have been run through like an old pair of boots. Enter dapolsertib, the fresh-faced newcomer in Menarini Group and Ryvu Therapeutics' arsenal, showing encouraging signals in early Phase II results. These...
Continue Reading